Market Overview

UPDATE: Dawson James Initiates Affymax at Market Outperform on Momentum

Related AFFY
Herb C. Cross to Join KaloBios as Chief Financial Officer
How to Protect Your Retirement Plans

Dawson James initiated coverage on Affymax (NASDAQ: AFFY) with a Market Outperform rating and a $32 price target.

Dawson James commented, "Commercialization of new products is always tricky, especially in the current environment; however, we believe Omontys is an ideal product for the dialysis market given the new “bundled” pricing structure. … In addition, the receipt of a permanent “J code” (taking effect January 1, 2013) from the Centers for Medicare and Medicaid Services (CMS) should help lubricate reimbursement conditions and persuade any hold-outs to make the conversion from Epogen to Omontys. As sales growth momentum continues, so also should share price appreciation."

Affymax closed at $23.55 on Monday.

Latest Ratings for AFFY

Mar 2013McNicoll Lewis VlakDowngradesSell
Feb 2013LazardDowngradesBuyNeutral
Feb 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for AFFY
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (AFFY)

View Comments and Join the Discussion!